Novartis Will Spend $600 Mil. On Cell Culture-Derived Influenza Vaccine Facility
This article was originally published in The Pink Sheet Daily
Executive Summary
Swiss company to start construction on the first such manufacturing plant in the U.S. in 2007.
You may also be interested in...
HHS Contracts Aim To Fund Adjuvant Vaccines Research
GSK, Novartis and Iomai are awarded multi-million dollar contracts to fund adjuvant-based pandemic influenza vaccine development.
HHS Contracts Aim To Fund Adjuvant Vaccines Research
GSK, Novartis and Iomai are awarded multi-million dollar contracts to fund adjuvant-based pandemic influenza vaccine development.
Novartis Global Vaccines Business To Be Headquartered In The U.S.
The Swiss drug maker says its new headquarters in Cambridge, Mass. should be fully staffed in the second quarter of 2007.